Institute for Myeloma and Bone Cancer Research Presents at ASH 2010
Online, December 6, 2010 (Newswire.com) - Institute for Myeloma and Bone Cancer Research (IMBCR) presented data regarding ongoing research on oncogenes, angiogenesis and tumor suppressors, drug resistance, pathophysiology and preclinical studies in multiple myeloma.
Poster Presentations:
1. Oncogenes and Tumor Suppressors
2. Molecular Pharmacology, Drug Resistance
3. Myeloma - Pathophysiology and Preclinical Studies, excluding Therapy: Multiple Myeloma - Microenvironment and New Animal Models
4. Myeloma - Pathophysiology and Preclinical
Oral Session:
1. Myeloma - Pathophysiology and Pre-Clinical Studies, excluding Therapy: Multiple Myeloma - Microenvironment and New Animal Models
About IMBCR
The Institute for Myeloma and Bone Cancer Research (IMBCR), established in 2004 as a 501 c (3) non-profit organization, is headquartered in Los Angeles, California. IMBCR is the only independent non-profit cancer research institute working to find improved treatment, and ultimately a cure for multiple myeloma, a cancer of the blood cells that reside in the bone marrow.
IMBCR research findings have also been presented at annual meetings of the American Society of Clinical Oncologists (ASCO), and the bi-annual International Myeloma Workshop in Greece. Our research has been published in publications including, Blood, Journal of Clinical Oncology, Proceedings of the National Academy of Sciences, Cancer, Clinical Cancer Research, Clinical Lymphoma and Myeloma, Oncogene, and the British Journal of Haematology.
For more information, please visit www.imbcr.org.
Contacts: James R. Berenson, MD, Medical & Scientific Director; jberenson@imbr.org. Haiming Chen, MD, Ph.D, Director of Research Laboratory hchen@imbcr.org. Zhi Wei Li, Ph.D, Principal Scientist for "The Cure Myeloma Project" zli@imbcr.org. Eric Sanchez, Director Animal Research; esanchez@imbcr.org. Cheryl A. Cross, MPH, Director of New Research Development; ccross@imbcr.org.
